Continuous delivery of energy or L-dopa: Identifying advantages and limitations of dbs and levodopa-carbidopa intestinal gel in the absence of head-to-head comparisons

Basal Ganglia

Volumn 2, Issue 4, 2012, Pages 221-226

  Johansson, Anders ^a,b   Nyholm, Dag ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Subthalamic nucleus Deep brain stimulation Levodopa carbidopa intestinal gel Parkinson's Disease

Indexed keywords

CARBIDOPA; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; EVIDENCE BASED MEDICINE; GEL; HUMAN; LONG TERM CARE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 84879166468     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.05.002     Document Type: Article

References (47)

1. Merola A et al. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011;26(4):664-70.
2. Fox SH et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl. 3):S2-41.
3. Clarke CE et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15(10):728-41.
4. De Gaspari D et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77(4):450-3.
5. Nyholm D et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009;119(5):345-8.
6. Antonini A et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011;258(4):579-85.
7. Carron R et al. High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review. J Neural Transm 2011;118(6):915-24.
8. Kleiner-Fisman G et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(Suppl. 14):S290-304.
9. Deuschl G et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355(9):896-908.
10. Follett KA et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362(22):2077-91.
11. Weaver FM et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301(1):63-73.
12. Williams A et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9(6):581-91.
13. Okun MS et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol 2012;11(2):140-9.
14. Zibetti M et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord 2011;26(13):2327-34.
15. Castrioto A et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68(12):1550-6.
16. Nilsson D et al. Long-term intraduodenal infusion of a water based levodopacarbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97(3):175-83.
17. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001;104(6): 343-8.
18. Nyholm D et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-23.
19. Nyholm D et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005;65(9):1506-7.
20. Antonini A et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22(8):1145-9.
21. Antonini A et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegenerative Dis 2008;5(3-4):244-6.
22. Eggert K et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31(3):151-66.
23. Nyholm D et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31(2):63-73.
24. Honig H et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24(10):1468-74.
25. Raudino F et al. Long-term experience with continuous duodenal levodopacarbidopa infusion (Duodopa): report of six patients. Neurol Sci 2009;30(1):85-6.
26. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24(7):993-1000.
27. Antonini A et al. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 2010;20(10):683-7.
28. Karlsborg M et al. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull 2010;57(6):A4155.
29. Puente V et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16(3):218-21.
30. Santos-Garcia D et al. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden. Eur J Neurol 2012.
31. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012.
32. Zrinzo L et al. Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg 2012;116(1):84-94.
33. Voges J et al. Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery-experiences from a single centre. J Neurol Neurosurg Psychiatry 2006;77(7):868-72.
34. Vergani F et al. Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. World Neurosurg 2010;73(4):338-44.
35. Doshi PK. Long-term surgical and hardware-related complications of deep brain stimulation. Stereotact Funct Neurosurg 2011;89(2):89-95.
36. Strutt AM et al. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol 2012;19(1):121-7.
37. Witt K et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008;7(7):605-14.
38. Parsons TD et al. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006;5(7):578-88.
39. Negreanu L et al. Duodopa infusion treatment: a point of view from the gastroenterologist. J Gastrointest Liver Dis 2011;20(3):325-7.
40. Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011;77(22):1947-50.
41. Klostermann F et al. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2011.
42. Muller T et al. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 2011;118(9):1329-33.
43. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63(5):886-91.
44. Santos-Garcia D et al. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol 2012.
45. Nyholm D et al. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 2011.
46. Elia AE et al. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol 2012;19(1):76-83.
47. Nyholm D et al. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin Neuropharmacol 2012;35(1): 6-14.